METHOD OF IMPROVING MUSCLE AND CONNECTIVE TISSUE WITH SHILAJIT
20210169927 · 2021-06-10
Assignee
Inventors
Cpc classification
A23V2002/00
HUMAN NECESSITIES
A61P21/00
HUMAN NECESSITIES
A61K31/194
HUMAN NECESSITIES
A23V2200/316
HUMAN NECESSITIES
A23L33/30
HUMAN NECESSITIES
A61K31/35
HUMAN NECESSITIES
A23V2002/00
HUMAN NECESSITIES
International classification
A23L33/00
HUMAN NECESSITIES
A61K31/194
HUMAN NECESSITIES
A61K31/35
HUMAN NECESSITIES
Abstract
The present invention is directed to methods for improving muscle and connective tissue with Shilajit, including reducing collagen degradation and reducing the loss of strength due to muscle fatigue. The present methods improve muscle building and repair as well as the health of skin, cartilage, connective tissues, muscle, vascular tissues, bones, and teeth, and treat collagen-related disorders such as arthritis and osteoporosis.
Claims
1. A method of reducing collagen degradation in a subject comprising the steps of: (a) providing a composition comprising Shilajit, or its individual components, or a combination of at least (i) and (ii) below, the Shilajit or individual components or combination comprising (i) at least 10,3% by weight combined of free dibenzo-α pyrones and dibenzo-α-pyrones conjugated with chromoproteins and (ii) at least 50% by weight of fulvic acids with dibenzo-α-pyrone core nucleus; (b) administering the composition to the subject to deliver the Shilajit or its individual components or combination to the subject's bloodstream and bodily tissues in an amount effective to reduce collagen degradation in the tissues of the subject; and (c) said Shilajit or components or combination thereof acting on said tissues to reduce collagen degradation therein.
2. The method of claim 1, wherein the Shilajit, individual components, or combination thereof in the composition is a standardized aqueous Shilajit extract.
3. The method of claim 2, wherein the standardized aqueous Shilajit extract is in dry powder form with 14-17% (w/w) combined of free dibenzo-a pyrones and dibenzo-α-pyrones conjugated with chromoproteins, and 59-62% (w/w) fulvic acids with dibenzo-α pyrone core nucleus.
4. The method of claim 2, wherein said composition is a dietary supplement and said administering step (b) is by oral administration of the dietary supplement.
5. The method of claim 4, wherein said effective amount of step (b) is about 50 mg to about 1500 mg of standardized aqueous Shilajit extract per day, and said subject is human.
6. The method of claim 4, wherein said effective amount of step (b) is 200 mg to 500 mg of standardized aqueous Shilajit extract per day, and said subject is human.
7. The method of claim 5, wherein said dietary supplement is administered daily for at least 8 weeks. 8, The method of claim 6, wherein said dietary supplement is administered daily for at least 8 weeks. 9, The method of claim 4, wherein said effective amount is about 1 to about 22 mg of the standardized aqueous Shilajit extract, per kilogram of the subject, per day.
10. The method of claim 9, wherein said effective amount is about 5 mg/kg to about 10 mg/kg.
11. The method of claim 10, wherein said dietary supplement is administered daily for at least 8 weeks.
12. The method of claim 5, wherein said subject is a human adult athlete having a baseline, pre-administration serum hydroxyproline concentration of at least 0.7 ug/ml.
13. The method of claim 12, said subject having a baseline, pre-administration serum hydroxyproline concentration of at least 2.0 ug/mL.
14. The method of claim 13, step (c) further comprising reducing serum hydroxyproline concentrations In the subject by 10-77%.
15. The method of claim 14, step (c) further comprising reducing serum hydroxyproline concentrations in the subject by at least 29%.
16. The method of claim 14, step (b) further comprising administering the standardized aqueous Shllajit extract daily for at least 8 weeks.
17. The method of claim 14, further comprising step (d) performing resistance training to increase the muscle strength and/or mass, and/or body weight of the subject.
18. The method of claim 5, wherein collagen degradation in step (c) is reduced in connective tissue of the subject, and said method supports and/or improves connective tissue health in the subject.
19. The method of claim 5, wherein collagen degradation in step (c) is reduced in tendons and/or ligaments of the subject, and said method supports and/or improves tendon and ligament health in the subject.
20. The method of claim 19, said method improving skeletal muscle strength, muscle building and muscle generation in the subject.
21. The method of claim 5, wherein collagen degradation in step (c) is reduced in the tissues of the subject, and said method supports and/or improves the health of said tissue or tissues.
22. The method of claim 5, wherein collagen degradation in step (c) is reduced in the subject's skeletal muscle tissue and/or associated connective tissue, said method further comprising the step of, after step (c), reducing muscle fatigue in the subject under or after fatiguing conditions.
23. The method of claim 22, wherein said effective amount is 100-1000 mg of the standardized aqueous Shilajit extract per day.
24. The method of claim 22, wherein collagen degradation in step (c) is reduced in the subject's skeletal muscle tissue and/or associated connective tissue, said method further comprising the step of, after step (c), increasing skeletal muscle strength in the subject.
25. The method of claim 24, further comprising step (d), performing resistance training to increase the muscle strength and/or mass, and/or body weight of the subject.
26. The method of claim 22, wherein said muscle fatigue is measured by a decline in Maximal Voluntary Isometric Contraction strength in the subject under or after fatiguing conditions, and the subject's Maximal Voluntary Isometric Contraction strength decline is reduced by at least 6% after administration of the Shilajit extract, as compared with pre-administration muscle strength decline.
27. The method of claim 26, wherein said decline in Maximal Voluntary Isometric Contraction strength is reduced by 6 to 25% after administration of the Shilajit extract.
28. The method of claim 5, wherein said subject has osteoporosis.
29. The method of claim 5, wherein said subject has arthritis.
30. A method of reducing muscle fatigue in a subject comprising the steps of: (a) providing a composition comprising Shilajit, or its individual components, or a combination of at feast (i) and (ii) below, the Shilajit or individual components or combination comprising (i) at least 10.3% combined by weight of free dibenzo-α-pyrones and dibenzo-α-pyrones conjugated with chromoproteins, and (ii) at least 50% by weight of fulvic acids with dibenzo-α-pyrone core nucleus; (b) administering an effective amount of the Shilajit or individual components or combination to the subject to deliver the Shilajit or individual components or combination to the subject's bloodstream and skeletal muscle tissue and/or associated connective tissue to at least reduce collagen degradation; (c) said Shilajit or components or combination thereof acting on the subject's skeletal muscle tissue and/or associated connective tissue to reduce collagen degeneration in said tissue or tissues; (d) introducing fatiguing conditions to the subject's skeletal muscle tissue; and (e) said skeletal muscle tissue retaining muscle strength under the fatiguing conditions and reducing muscle fatigue.
31. The method of claim 30, wherein the Shilajit, individual components, or combination in the composition is a standardized aqueous Shilajit extract.
32. The method of claim 31, wherein the standardized aqueous Shilajit extract is in dry powder form with 1447% (w/w) combined of free dibenzo-a pyrones and dibenzo-α-pyrones conjugated with chromoproteins, and 59-62% (w/w) fulvic acids with dibenzo-α pyrone core nucleus.
33. The method of claim 31, wherein said composition is a dietary supplement and said administering step is by oral administration of the dietary supplement, daily.
34. The method of claim 33, wherein said subject is human and said effective amount is about 50 to about 1500 mg per day of the Shilajit.
35. The method of claim 33, wherein said subject is human and said effective amount is about 200 mg to about 500 mg per day of the Shilajit.
36. The method of claim 34, wherein said dietary supplement is administered daily for at least 8 weeks.
37. The method of claim 33, wherein said effective amount is about 1 to about 22 mg of the standardized Shilajit per kilogram of the subject.
38. The method of claim 37, wherein said effective amount is about 5 mg/kg to about 10 mg/kg.
39. The method of claim 38, wherein said dietary supplement is administered daily for at least 8 weeks.
40. The method of claim 34, wherein the subject is human and an adult athlete having a baseline, pre-administration serum hydroxyproline concentration of at least 0.7 ug/ml.
41. The method of claim 40, said subject having a baseline, pre-administration serum hydroxyproline concentration of at least 2.0 ug/ml.
42. The method of claim 41, step (c) further comprising reducing serum hydroxyproline concentration in the subject by 10-77%,
43. The method of claim 42, step (c) further comprising reducing serum hydroxyproline concentration in the subject by at least 29%.
44. The method of claim 41, further comprising the step of said athlete performing resistance training to increase the muscle strength and/or mass, and/or body weight of the subject.
45. The method of claim 34, said method improving the retention of muscle strength during or after fatiguing conditions.
46. The method of claim 34, wherein said muscle fatigue is measured by a decline in Maximal Voluntary Isometric Contraction strength in the subject under or after fatiguing conditions, and the subject's Maximal Voluntary Isometric Contraction strength decline is reduced by at least 6% after administration of the Shilajit extract, as compared with pre-administration muscle strength decline.
47. The method of claim 46, wherein said decline in Maximal Voluntary Isometric Contraction strength is reduced by 6 to 25% after administration of the Shilajit extract.
48. The method of claim 31, wherein said Shilajit or individual components or combination includes at least 60% fulvic acids with dibenzo-at-pyrone core nucleus.
49. A method of improving skeletal muscle tissue and/or connective tissue in a subject comprising the steps of: (a) providing a composition comprising Shilajit, or its individual components, or a combination of at least (i) and (ii) below, the Shilajit or individual components or combination comprising (i) at least 10.3% combined by weight of free dibenzo-α-pyrones and dibenzo-α-pyrones conjugated with chromoproteins, and (ii) at least 50% by weight of fulvic acids with dibenzo-α-pyrone core nucleus; (b) administering an effective amount of the Shilajit or individual components or combination to the subject to deliver the Shilajit or individual components or combination to the subject's bloodstream and skeletal muscle tissue and/or associated connective tissue at least to reduce collagen degradation in those tissues; and (c) said Shilajit or components or combination thereof acting on said skeletal muscle tissue and/or associated connective tissue to reduce collagen degradation and thereby improve the skeletal muscle and/or associated connective tissue.
50. The method of claim 49, wherein the Shilajit, individual components, or combination thereof in the composition is a standardized aqueous Shilajit extract.
51. The method of claim 50, wherein said composition is a dietary supplement and said administering step (b) is by oral administration of the dietary supplement.
52. The method of claim 51, wherein said effective amount of step (b) is about 50 mg to about 1500 mg of standardized aqueous Shilajit extract per day, and said subject is human.
53. The method of claim 52, wherein said effective amount of step (b) is 200 mg to 500 mg of standardized aqueous Shilajit extract per day, and said subject is human.
54. The method of claim 51, wherein said effective amount is about 1 to about 22 mg of the standardized aqueous Shilajit extract, per kilogram of the subject per day.
55. The method of claim 52, wherein said dietary supplement is administered daily for at least 8 weeks.
56. The method of claim 52, further comprising the step of performing resistance training to increase muscular strength and/or mass, and/or the body weight of the subject,
57. A method of treating osteoporosis or arthritis in a subject, comprising the steps of (a) providing a composition comprising Shilajit, or its individual components, or a combination of at least (i) and (ii) below, the Shilajit or individual components or combination comprising (i) at least 10.3% by weight combined of free dibenzo-α pyrones and dibenzo-α-pyrones conjugated with chromoproteins and (ii) at least 50% by weight of fulvic acids with dibenzo-α-pyrone core nucleus; (b) administering the composition to the bloodstream of the subject to deliver the Shilajit or its individual components or combination to the subject's bloodstream and bodily tissues in an amount effective to reduce collagen degradation in the tissues of the subject; and (c) said Shilajit or components or combination thereof acting on said tissues to reduce collagen degradation therein.
58. The method of claim 57, wherein the Shilajit, individual components, or combination thereof in the composition is a standardized aqueous Shilajit extract.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0050]
[0051]
[0052]
DETAILED DESCRIPTION
[0053] The utility of Shilajit for preventing or reducing collagen degradation and reducing muscle fatigue, and thus increasing muscular strength with resulting muscle building and regeneration, is completely novel and of tremendous value to mammals, including humans.
[0054] The administration of Shilajit compositions according to the present invention significantly reduces muscle fatigue under fatiguing conditions, as shown for instance by the 6% reduction in MVIC decline shown in
[0055] The below definitions and discussion are intended to guide understanding but are not intended to be limiting with regard to other disclosures in this application. References to percentage (%) in compositions of the present invention refers to the % by weight of a given component to the total weight of the composition being discussed, also signified by “w/w”, unless stated otherwise.
[0056] “Shilajit” is a rock exudate containing fulvic acids (“FAs”) as its main components, along with dibenzo-α-pyrones (“DSPs”) and DBP chromoproteins, humic acid, and more than forty (40) minerals. A composition of this invention comprises Shilajit, or its individual components, or a combination of at least (i) and (ii) below, the Shilajit or individual components or combination comprising and defined as (i) at least 10.3% by weight combined of free dibenzo-a pyrones and dibenzo-α-pyrones conjugated with chromoproteins and (ii) at least 50% by weight of fulvic acids with DBP core nucleus
[0057] In an embodiment, Shilajit according to this invention is a standardized aqueous extract of Shilajit (“standardized aqueous Shilajit extract”) containing at least 50% (w/w) fulvic acids with DRP core nucleus and at least 10.3% (w/w) of free DBP plus DBP conjugated with chromoproteins, and for instance more than 40 microminerals. The standardized aqueous Shilajit extract according to this invention is “PrimaVie® Shilajit”. PrimaVie® is a registered US trademark under which standardized aqueous Shilajit extract is sold, PrimaVie® Shilajit is described in U.S. Pat. Nos. 6,869,6:12 and 6,440,436, each of which is incorporated by reference herein for the purpose of describing PrimaVie® Shilajit.
[0058] In a further embodiment, said standardized aqueous Shilajit extract (“PrimaVie® Shilajit”) is a dry powder, having the appearance of a fine, brown to dark-brown, free-flowing powder; and further conforms to one or more of the following parameters: a water-soluble extractive value of at least 80% w/w; water in an amount of 0-6% (w/w); E.sub.4/E.sub.6 at 465/665 nm of 7.0-9.5; pH (2.0% aqueous dispersion) at least 5; lead at no more than 2 ppm, arsenic at no more than 3 ppm, and mercury at no more than 0.5 ppm; and a microbiological profile having not more than 5000 CFU/g aerobic bacteria (USP<2021>), not more than 1000 CFU/g yeast and mold (USP<2021>), with Escherichia coli (AOAC 991.14), Pseudomonas aeruginosa (USP<62>), Staphylococcus aureus (USP<2022>), and Candida albicans (custom) all absent in 1 g of said dry powder and Salmonella species (modified AOAC 998.09) absent in 10 g of said dry powder. In an embodiment, the standardized aqueous Shilajit extract of the present invention conforms to all of these parameters.
[0059] In a further embodiment, said standardized aqueous Shilajit extract is in dry powder form and further conforms to one or more of the following parameters: a water-soluble extractive value of about 93-96% (w/w), combined DBPs of about 14-17% (w/w), Fulvic acids with DBP core nucleus of about 59-62% (w/w), water in an amount of about 1-4% (w/w), E.sub.4/E.sub.6 at 465/665 nm at about 7-8, pH (2.0% aqueous dispersion) at about 6-8, lead in an amount less than 1 ppm, arsenic in an amount less than 0.6 ppm, mercury in an amount less than 0.01 ppm, less than about 500 CFU/g aerobic bacteria, less than 100 CFU/g yeast and mold, with E. coli, Salmonella, Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans not measurably present. In an embodiment, the standardized aqueous Shilajit extract of the present invention conforms to all of these parameters.
[0060] In a further embodiment, said standardized aqueous Shilajit extract is in dry powder form and conforms to one or more of the following parameters: a water-soluble extractive value of 94.5% (w/w), combined DBPs of 15.67% (w/w), fulvic acids with DBP core nucleus of 60.81% (w/w), water in an amount of 2.75% (w/w), E.sub.4/E.sub.6 at 465/665 nm of 7.22, pH (2.0% aqueous dispersion) of 7.41, lead in an amount of 0.882 ppm, arsenic in an amount of 0.406 ppm, mercury in an amount less than 0.004 ppm, aerobic bacteria measured at 250 CFU/g or less, and yeast and mold at less than 70 CFU/g. E. coli, Salmonella, Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans are not measurably present. In an embodiment, the standardized aqueous Shilajit extract of the present invention conforms to all of these parameters.
[0061] HPLC (High Pressure Liquid Chromatography) and HPTLC (High Pressure Thin Layer Chromatography) may be used to confirm the conformance of a standardized aqueous Shilajit extract of the present invention to e.g. fulvic acid and DBP parameters above, and other parameters as appropriate. In an embodiment, the standardized aqueous Shilajit extract in dry powder form is stable for 3 years or more. In an embodiment, the powdered extract is stored at 15° C. to 25° C., and in a container that avoids exposure of the powdered extract to light.
[0062] In an embodiment, standardized aqueous Shilajit extract (PrimaVie® Shilajit) is for nutraceutical use. In an embodiment, standardized aqueous Shilajit extract (PrimaVie® Shilajit) is for pharmaceutical use. In an embodiment, a composition of this invention is a standardized aqueous Shilajit extract as discussed above (PrimaVie® Shilajit). In another embodiment, a composition of this invention comprises the standardized aqueous Shilajit extract discussed above (PrimaVie® Shilajit).
[0063] In addition, a composition of the present invention may include excipients including for instance gelatin, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, and/or magnesium stearate.
[0064] Shilajit or its equivalent(s) in embodiments of the present invention may be formulated into compositions including nutraceutical or pharmaceutical dosage forms comprising tablets, capsules, powders, liquids, chews, gummies, transdermals, injectables, etc, using standard excipients and formulation techniques in the industry.
[0065] A composition of the present invention as disclosed for instance in the below Examples may be made for instance according to the following steps: blending ingredients (except magnesium stearate, if present) in a 16 quart blender equipped with a sift-and-blend option and a 30 mesh stainless steel screen attachment for 15 minutes with screening at 1500 rpm. If any lumps remain, blending should continue for an additional 10 minutes at 1500 rpm to remove the lumps. Thereafter, magnesium stearate may be added to the blend, and the resulting powder blended for 5 minutes without using a sift-and-blend option. The blended composition may be stored in sealed containers, for instance avoiding light, for instance at 15° C.-25° C., for up to 3 years. In an embodiment, the composition is prepared under conditions of less than 50% relative humidity. In another embodiment, the composition is prepared under conditions of less than 40% relative humidity.
[0066] In an embodiment, a composition of the present invention such as the above blended composition may be encapsulated by filling capsules with an amount of the blended composition that will provide for instance 125 mg, 250 mg, 500 mg, or more of the purified Shilajit dry powder extract in the capsule. Other amounts of Shilajit (or its components or the combination with (i) and (ii) as defined above) may be included in the capsules or other delivery method. In an embodiment, a daily dose of Shilajit (or its components or combination as defined above) is provided as a discrete dose unit, or divided into 2 or more discrete dose units.
[0067] In an embodiment, a 125 mg Shilajit capsule may contain a blended composition comprising 125 mg standardized aqueous Shilajit extract (PrirnaVie® Shilajit), 100 mg microcrystalline cellulose (NF, Type 102), 10 mg croscarmellose sodium (NF), 2 mg silicon dioxide (NF, fumed, Cab-O-Sil®), 2 mg magnesium stearate (NF, vegetable derived). The total capsule fill weight of this composition is 239 mg. A type 1 capsule may be used, for instance a capsule weighing 74 mg, for a total capsule weight of 313 mg,
[0068] In an embodiment, a 250 mg Shilajit capsule may contain a blended composition comprising 250 mg standardized aqueous Shilajit extract (PrimaVie® Shilajit), 50 mg microcrystalline cellulose (NF, Type 102), 10 mg croscarmellose sodium (NF), 3 mg silicon dioxide (NF, fumed,)Cab-O-Sil®), 3 mg magnesium stea rate (NF, vegetable derived)). The total capsule fill weight of this composition is 316 mg. A type 1 capsule may be used, for instance a capsule weighing 74 mg, for a total capsule weight of 390 mg.
[0069] An “effective amount” or “amount effective . . . ” according to the present invention refers to an amount of Shilajit (or its individual components or a combination of its components as defined above), which when administered to a human or other subject, is effective in reducing and/or preventing collagen degradation in the subject's bodily tissues and/or reducing muscle fatigue in the subject's skeletal muscle tissue under fatiguing conditions. The present invention reduces the decline in strength typically accompanying muscle fatigue, thus retaining muscular strength under fatiguing conditions, and increases available collagen by reducing collagen degradation, thereby supporting tissue health, and strength and elasticity. An “effective amount” of Shilajit according to the present invention will allow the Shilajit (or its individual components or combination as defined throughout this application) to reach the subject's bloodstream and tissue including skeletal muscle tissue and reduce muscle fatigue in the skeletal muscle after the muscle has worked under fatiguing conditions, as shown in
[0070] In an embodiment of a method of the present invention, an effective amount of Shilajit (or its individual components or a combination of its components as defined above) in a human subject is about 50-1500 mg per day, or 100-1000 mg per day, or another amount within these ranges. For instance, in an embodiment of a method of the present invention, an effective amount of Shilajit in a human subject is 200-500 mg/day, In an embodiment, the effective amount is 250 mg/day or 500 mg/day. In an embodiment, about 400-600 mg/day is an effective amount. In an embodiment, an effective amount to be administered to a human subject is 50 mg-2000 mg, including 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, 1500 mg, 1600 mg, 1700 mg, 1800 mg, 1900 mg, 2000 mg, and any range including the above. In another embodiment, an effective amount is administered daily for at least 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, and so on, and administered chronically (e.g. 6 months or more) if desired.
[0071] In an embodiment, the effective amount to be administered is calculated per kilogram of body weight of the subject. For instance, a 500 mg daily dose in a 94 kg human adult male athlete is about 5.3 mg Shilajit per kilogram. In an embodiment, at least 0.6 mg Shilajit is administered to a human subject per kilogram. A 1500 mg daily dose in a 120 kg subject such as an adult male athlete is about 12.5 mg/kg. A 50 mg dose in a 70 kg subject is about 0.7 mg/kg subject. A 250 mg dose in an 80 kg subject is about 3 mg Shilajit/kg. A 600 mg daily dose In a 50 kg female athlete is administered in an amount of about 12 mg Shilajit/kg female athlete. In an embodiment, about 1 to about 15 mg Shilajit per day, or about 3 to about 12 mg per day, is administered to a subject. In an embodiment, about 5.5-6.5 mg Shilajit/kg human or other subject, or 6 mg/kg, is administered. In an embodiment, when calculating a dose of Shilajit according to the present invention, the dose should be equivalent to providing 50-2000, or 100-1000, mg Shilajit to a 70-94 kg subject. For a 5 kg dog, a dose of 6 mg Shilajit/kg of the subject may be about 30 mg daily. Similarly, for a 700 kg horse, an effective amount of Shilajit may be 700 kg horse×10 mg Shilajit/kg=about 7 grams Shilajit daily for the horse. In an embodiment, a dose of 1-10 mg/kg, or 3-5 mg/kg, or 5-6 mg/kg, or 6 mg -10 mg Shilajit/kg subject is administered.
[0072] “Administering” or “administration” of a composition of the present invention or the like refers to introducing the composition (including Shilajit or its individual components or a combination of components as defined above, and preferably Shilajit PrimaVie®) into the body of the human or other mammalian subject, so that the Shilajit is delivered to the subject's bloodstream and tissues, exposing the tissues to the Shilajit so that the Shilajit may change the tissues from their pre-administration state. The Shilajit interacts with the tissues to reduce collagen degradation, as evidenced by the decrease in hydroxyproline shown in
[0073] A “dietary supplement” according to the present invention refers to a composition of the present invention which is administered as an addition to a subject's diet, which is not a natural or conventional food, which effectively reduces collagen degradation and/or reduces muscle fatigue when administered to the human or other mammal over a period of time. In an embodiment, a dietary supplement containing an effective amount of Shilajit according to the present invention is administered orally. In an embodiment, the dietary supplement is administered daily; in an embodiment, the dietary supplement is administered daily for 8 weeks or more, or for another period of time according to the present invention. A dietary supplement may be formulated into various forms, as discussed throughout this application.
[0074] “Connective tissue” according to the present invention refers to tissue that contains collagen and connects, supports, or separates other tissues or organs, typically having relatively few cells embedded in an amorphous matrix, with collagen and often other fibers. Connective tissue includes for instance tendons, ligaments, and the endomysium of muscle tissue.
[0075] “Collagen degradation” according to the present invention refers to the breakdown of the protein collagen in the body of a subject. Serum levels of hydroxyproline (HYP) are used as an indicator of collagen degradation in the present invention. Reducing collagen degradation according to the present invention retains collagen in a subject's bodily tissues, improving for instance muscle tissue and its performance under fatiguing conditions, muscle building, and muscle repair and improving the health of collagen-containing tissues such as skin, cartilage, connective tissue(s), muscle, vascular tissue(s), bone(s), and teeth in the body of a subject, in particular a human subject, through the administration of Shilajit.
[0076] The reduction of collagen degradation and hence retention of collagen in bodily tissues by Shilajit such as PrimaVie® Shilajit treats collagen-related disorders including for instance osteoporosis and arthritis, in effective amounts such as discussed above. Also as discussed above, osteoporosis is experienced with age and is associated with reduced levels of collagen in the skin and bones. In an embodiment, a method of the present invention treats osteoporosis by providing and administering a composition such as PrimaVie® Shilajit in an effective amount to a subject having osteoporosis, so that the Shilajit bioactives enter the bloodstream and bodily tissues such as skin, bone, and associated connective tissues, and decrease collagen degradation in those tissues, as shown by the reduction of serum hydroxyproline (HYP) in subjects that have taken PrimaVie® Shilajit. By reducing collagen degradation in these tissues, the present methods increase the amount of collagen in the tissue, slowing and/or stopping the progress of the disease, and hence treating osteoporosis in the subject. The present methods may further treat osteoporosis for instance by retaining muscle strength, as discussed throughout this application.
[0077] As discussed above, arthritis is an inflammation of the joints, causing swelling and pain, and gradually degrades collagen in the joints, In an embodiment, a method of the present invention treats arthritis by providing and administering a composition such as PrimaVie® Shilajit in an effective amount to a subject having arthritis, so that the Shilajit bioactives enter the bloodstream and bodily tissues such as cartilage, bone, and associated tissues such as ligaments, tendons, and blood vessels, by reducing collagen degradation in those tissues, as shown by the reduction of serum hydroxyproline (HYP) in subjects that have taken PrimaVie® Shilajit. By reducing collagen degradation in these tissues, the present methods increase the amount of collagen in the tissue, slowing and/or stopping the progress of the disease, and hence treating arthritis in the subject. The present methods may further treat arthritis for instance by retaining muscle strength, as discussed throughout this application.
[0078] Collagen is a structural protein in humans as well as other mammals such as dogs and horses. In an embodiment, an effective amount of Shilajit for treating collagen-related disorders such as osteoporosis or arthritis is the same as an effective amount for reducing collagen degradation and/or reducing muscle fatigue and retaining muscle strength under fatiguing conditions according to the present invention—in humans, about 50 mg Shilajit to about 1500 mg Shilajit daily; in other mammals, about 1-22 mg/kg. In an embodiment, the effective amount of Shilajit for treating a non-human mammal such as a dog or horse is calculated as mg Shilajit per kg of subject.
[0079] A subject of the present invention that may be administered Shilajit or its individual components or a combination of said components, preferably PrimaVie® Shilajit, is a human or other mammal, such as a horse or dog. In an embodiment, the subject is a human. In an embodiment, the subject is an adult male human. In an embodiment, the subject is an adult female human. In an embodiment, the subject is about 70-95 kg, as in the below Example. In an embodiment, a subject according to the present invention is a human adult having strength as measured by MVIC of at least 350-360 N-m, for instance 355-560 N-m, or 400-550 N-m, as measured in the Example below, prior to Shilajit supplementation. In an embodiment, a subject according to the present invention is a human adult having an MVIC strength of at least 210-560 N-m, as measured in the Example below, prior to Shilajit supplementation. In an embodiment, a subject according to the present invention is a human adult having a baseline, pre-administration serum concentration of hydroxyproline of at least 0.65 ug per mL, for instance in the amount of 0.65-5 ug/ml. In an embodiment, a subject according to the present invention is a human adult having a baseline, pre-administration serum concentration of hydroxyproline of at least 1.85 ug per ml., preferably at least 2 ug per mL, and for instance in the range of 2-5 ug HYP per mL, Baseline serum hydroxyproline may be reduced in a subject of this invention, for instance by 29% as discussed above and shown in
[0080] An “athlete” or “athletic subject” according to the present invention refers to a human subject that regularly exercises or plays sports, recreationally or professionally. In an embodiment, a subject according to the present invention is an athletic subject as described in the below Example.
[0081] “Physical activity” according to the present invention refers to activity such as exercise, sports, and/or work such as physical labor by a human.
[0082] “Muscle fatigue” or “fatigue” according to the present invention refers to a decrease in skeletal muscle strength during and/or after fatiguing conditions. Fatiguing conditions include repeated and/or extended physical activity using skeletal muscle such as exercise, sports, and/or work. In an embodiment, fatiguing conditions include the fatiguing protocol employed in the Example described herein: 2 bouts of 50 consecutive maximal, bilateral, concentric, isokinetic leg extension muscle actions. “Muscle strength” and the like according to the present invention refers to the maximum or near-maximum force a muscle can exert against external resistance, for instance in a single effort. Muscle strength is measured in an embodiment of the present invention as MVIC in the below Example. The loss of muscle strength due to muscle fatigue in a subject administered Shilajit in accordance with the present invention is reduced, for instance as shown in the below Example and
[0083] “Resistance training” according to the present invention refers to a type of exercise that improves muscle fitness including for instance muscle strength, and also for instance muscle power and/or endurance, by causing muscles to contract against external resistance. In an embodiment, the external resistance is provided by dumbbells, a weight-lifting machine, or an individual's own body weight.
[0084] “Health” according to the present invention generally refers to tissues of the subject that are functioning properly, that are regular and intact. For instance, as discussed above, healthy skin is firm, elastic, and hydrated, and undergoes reasonably prompt wound healing. Healthy bone is hard enough to perform its intended functions, and not weak or brittle. Cartilage, tendons, and ligaments are soft, fibrous, and elastic, not brittle or easily injured. In contrast, unhealthy, or even diseased, tissues include irregular or underperforming connective tissues, poor wound healing, brittle bones, deformities, and the like, for instance as discussed above regarding collagen-related disorders and degradation of collagen. Improvements in the health of tissues of the body, in their condition and status, may include improving healthy aspects of the tissue, such as improving the strength and/or elasticity of muscle, connective tissue, and/or skin, per the present methods.
[0085] The present invention may be further understood in connection with the following Example and embodiments. The following non-limiting Example and embodiments described throughout this application are provided to illustrate the invention.
EXAMPLE
[0086] The effects of 8 weeks Shilajit supplementation (i.e. administration according to the present invention) at 250 mg.Math.d.sup.−1 (low dose) and 500 mg.Math.d.sup.−1 (high dose) versus placebo on maximal voluntary isometric contraction (MVIC) strength, fatigue-induced percent decline in strength, and serum HYP, were examined. This Example demonstrates at least that 8 weeks of PrimaVie® Shilajit supplementation at 500 mg.Math.d.sup.−1 promotes the retention of muscular strength following a fatiguing protocol and reduced baseline HYP. These findings are particularly associated with the stronger subjects and those with highest pre-supplementation levels of baseline HYP. Thus, 8 weeks of PrimaVie® Shilajit supplementation at 500 mg.Math.d.sup.−1 elicited favorable muscle and connective tissue adaptations.
Methods
Study Design
[0087] The present double-blind, placebo-controlled study followed the timeline in
Subjects
[0088] Sixty-three recreationally trained (Pescatello L S. “Clinical exercise testing” ACSM's Guidelines for Exercise Testing and Prescription Philadelphia, Pa.: Wolters Kluwer/Lippincott Williams & Wilkins Health. 2014:114-41) men (
Supplement and Supplementation
[0089] The subjects ingested a low dose (250 mg.Math.d.sup.−1 in one capsule) of PrimaVie® Shilajit (Natreon Inc., New Brunswick, N.J.), a high dose (500 mg.Math.d.sup.−1 in one capsule) of PrimaVie® Shilajit, or a placebo for eight weeks. The PrimaVie® Shilajit in the capsules was a purified and standardized aqueous extract of Shilajit in dry powder form as discussed above, having as bioactives 60.8% (w/w) fulvic acids with DBP core nucleus and 15.7% (w/w) of free DBP plus DBP conjugated with chromoproteins.
[0090] All capsules were Identical in size and appearance. Capsules containing PrimaVie® Shilajit, 250 mg or 500 mg, and placebo were ail supplied by Natreon, Inc. (New Brunswick, N.J.). All capsules included a blend of microcrystalline cellulose, croscarmellose sodium, silicon dioxide (fumed), and magnesium stearate, with Shilajit capsules further including 250 mg or 500 mg of the dry powder Shilajit extract described above.
[0091] 250 mg Shilajit capsules contained, per unit dose capsule, a blended composition comprising 250 mg standardized aqueous Shilajit extract (PrimaVie® Shilajit), 50 mg microcrystalline cellulose (NF, Type 102), 10 mg croscarmellose sodium (NF), 3 mg silicon dioxide (NF, fumed, Cab-O-Sir), 3 mg magnesium stearate (NF, vegetable derived)). As the empty capsule (size 1) weighed 74 mg, the total weight of the 250 mg Shilajit capsules was 390 mg per capsule,
Procedures
Familiarization Visit
[0092] During the familiarization visit, the subjects performed submaximal (50-70% effort) and maximal, bilateral, isometric leg extension muscle actions as well as submaximal and maximal, bilateral, concentric, Isokinetic (180°.Math.s.sup.−1) leg extension muscle actions. All muscle actions were performed on a calibrated Cybex 6000 isokinetic dynamometer (Cybex International Inc. Medway, Mass.). Following the orientation, the subjects scheduled their first testing visit and were instructed to record their diet (MyFitnessPal, Inc.) during the three days before their scheduled testing visit 1. Also, the subjects scheduled their first fasting (12 hr overnight fast) baseline blood draw prior to their scheduled testing visit 1. The subjects were instructed to refrain from exercise for 48-hrs prior to testing visit 1,
Testing Visit 1
[0093] All testing visits were scheduled before noon, and upon arrival/ each subject returned his 3-day dietary recall. The subjects performed a standard warm-up of 10 bilateral, isokinetic (180°.Math.s.sup.−1) leg extension muscle actions at a self-selected intensity of approximately 50-70% effort, Following 2 min of rest, the subjects performed 2, 6 s pretest MVICs at a knee joint angle of 120° (where 180° corresponds to full leg extension at the knee). Following the determination of MVIC, the subjects completed a fatiguing protocol that consisted of 2 bouts of 50 consecutive maximal, bilateral, concentric, isokinetic leg extension muscle actions separated by 2 min of rest. Each concentric muscle action was performed through a 90° range of motion (90° to 180° of leg extension). Thus, a total of 100 maximal, bilateral, concentric, isokinetic leg extension muscle actions were completed within a 5 min period. Following the fatiguing protocol, the subjects completed 2, 6 s posttest MVICs utilizing the same procedures as the pretest MVIC trial. Following the testing visit 1 exercise procedures, the subjects were scheduled to complete a fasted (12 hr overnight) 48-hr post-exercise blood draw. In addition, the subjects were instructed not to perform additional exercise between the testing visit 1 and the 48-hr post-exercise blood draw visit.
48 hr Post-Exercise Blood Draw Visit
[0094] Upon arrival, the subjects confirmed adherence to the overnight fast as well as not performing additional exercise since testing visit 1. Following confirmation, a fasted blood sample was collected, and the subjects started supplementation. Furthermore, the subjects were instructed to take the supplement once daily far 8 weeks (56 days) and to maintain their typical exercise and dietary habits.
8 weeks Shilalit Supplementation
[0095] Throughout the 8 weeks of Shilajit supplementation, the subjects were contacted biweekly to promote adherence to supplementation as well as to ensure that no subjects had experienced any adverse effects possibly related to the supplement. During the last week of supplementation, the subjects scheduled the post-supplementation baseline blood draw visit as well as testing visit 2. The subjects were reminded to fast overnight prior to the post-supplementation baseline blood collection visit, to avoid performing any exercise 48-hr prior to testing visit 2, and to record their diet for 3 days before testing visit 2.
Testing Visit 2
[0096] Following the 8 weeks of Shilajit supplementation and the post-supplementation baseline blood draw visit, the subjects returned to the laboratory and provided their 3-day dietary analysis, The subjects then repeated the same testing procedures as testing visit 1. Following the completion of all testing procedures, the subjects were scheduled for their 48 hr past-exercise blood collection. Again, the subjects were instructed not to exercise and to complete an overnight 12 hr fast prior to the 48 hr post-exercise blood draw. Furthermore, the subjects returned any remaining supplement, so that adherence could be documented.
Determination of Strength, Percent Decline, and Collagen Degradation
[0097] During testing visits 1 and 2, concentric peak torque, MVIC, percent decline in MVIC, and percent decline in peak torque were determined. For concentric peak torque, the mean of the first five repetitions of the first bout of 50 maximal, bilateral, concentric isokinetic leg extension muscle actions was defined as pretest concentric peak torque, and the mean of the last five repetitions of the second bout of 50 maximal, bilateral, concentric isokinetic leg extension muscle actions was defined as posttest concentric peak torque. In addition, pretest MVIC and posttest MVIC were defined as the greatest torque produced during the 2 MVIC muscle actions for each test. Furthermore, percent decline in MVIC and percent decline in peak torque were determined with the following equations:
[0098] Each subject provided 8 mL of whole blood from the antecubital vein at pre-supplementation baseline and 48 hrs post-exercise as well as at post-supplementation baseline and 48 hrs post-exercise. Thus, there was a total of 252 (4 samples per subject) blood samples. Following the blood draws, the samples were each centrifuged and stored at −80° C. Subsequently, 100 μL of each individual sample was aliquoted into 2 mL screw cap tubes and prepared for the tandem technique of high-performance liquid chromatography mass spectrometry, Furthermore, the column used was ACCQ-TAG Ultra C18 1.7 μm, 2.1×100 mm, with mobile phase A, 100% Eluent A, mobile phase B, 10:90 Eluent B: Milli-Q water, mobile phase C, Milli-Q water, and mobile phase 0, 100% Eluent B. The flow rate was at 0.7 mL/min, the column oven was at 45° C., and the runtime was 13 min per sample. Standard curves were used to calculate the concentration of HYP in the samples from the peak area detected, using the following formula:
Serum HYP Concentration (μg.Math.mL.sup.−1)= EQN (3) [0099] (peak area HYP)/(peak area internal standard)•(Volume of internal standard•concentration of internal standard spike)/(slope from the standard curve•(molecular weight HYP)/1.000/volume of starting material)
Statistical Analyses
[0100] Test-retest reliability for MVIC, concentric peak torque, and baseline HYP were examined for the pre-test, pre-supplementation versus pre-test, post-supplementation measurements. Repeated measures ANOVAs were used to evaluate systematic error, and the 2,k model (Weir, “Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM” J Strength Cond Res 2005; 19(1):231-40) was used to determine the intraclass correlation coefficient (ICC) and standard error of the measurements (SEM).
[0101] Each dependent variable (MVIC, concentric peak torque, and HYP levels) was statistically analyzed using a 3 (Group: Low Dose, High Dose, Placebo)×2 (Visit: Testing Visit 1, Testing Visit 2)×2 (Fatigue: Pretest, Posttest) mixed factorial ANOVA to examine mean differences for absolute values. In addition, ANCOVA was used to examine post-supplementation differences between groups for percent decline in MVIC, percent decline in peak torque, percent change in baseline to 48 hrs post-exercise HYP levels, and percent change in baseline HYP levels covarying for pre-supplementation values. Huck S W et al., “Using a repeated measures ANOVA to analyze the data from a pretest-posttest design: A potentially confusing task” Psychol Bull 1975; 82(4):511; Vincent et al., “Statistics in Kinesiology. Human Kinetics” Champaign (IL): 2012. Furthermore, paired t-tests were used to examine pre-supplementation versus post-supplementation for total caloric intake, carbohydrates, proteins, and fats.
[0102] Additional analyses were performed separately for sub-samples of each group that were dichotomized at the 50.sup.th percentile (median) for pre-supplementation MVIC, concentric peak torque, and baseline HYP levels.
[0103] Pre-supplementation measurements of MVIC ranged from about 200-560 N-m. The highest and strongest pre-supplementation MVIC measurements (upper 50.sup.th percentile) ranged from about 360 N-m to about 560 N-m. In the lower 50.sup.th percentile, MVIC strength ranged from about 215 N-m to about 350 N-m. See Tables 1A, 1B, and 1C for further data. The above ranges are taken from data from these tables. Similar or other ranges may be derived from the Tables as needed.
[0104] Pre-supplementation peak torque (Set 1) ranged from about 148-331. Upper and lower 50.sup.th percentile groupings of subjects were the same as the groupings for MVIC measurements. See Tables 2A, 2B, and 2C for further data. The above range is taken from data from these tables. Similar or other ranges may be derived from the Tables as needed.
[0105] Pre-supplementation baseline serum HYP ranged from about 0.65 to about 5 ug/ml. Pre-supplementation baseline serum HYP levels in the upper 50th percentile ranged from 1.86-4.80 ug per mL, Pre-supplementation baseline serum HYP levels in the lower 50.sup.th percentile ranged from about 0.7 to about 1.9 ug per mL. See Tables 3A, 3B, and 3C for further data. The above ranges are taken from data from these tables. Similar or other ranges may be derived from the Tables as needed.
[0106] For each dependent variable, a 3 (Group: Low Dose, High Dose, Placebo)×2 (Visit: Testing Visit 1, Testing Visit 2)×2 (Fatigue: Pretest, Posttest) mixed factorial ANOVA was used to examine mean differences in absolute values separately for the upper 50th percentile sub-sample (n=10 per group for each dependent variable) and the lower 50.sup.th percentile sub-sample (n=11 per group for each dependent variable). Also, for each sub-sample, ANCOVAs were used to examine post-supplementation differences between groups for percent decline in MVIC, percent decline in peak torque, percent change in baseline to 48 hrs post-exercise HYP levels, and baseline HYP levels covaried for pre-supplementation values.
[0107] Therefore, a total of nine mixed factorial ANOVAs and twelve ANCOVAs were used to examine mean differences in MVIC, concentric peak torque, percent decline in MVIC, percent decline in concentric peak torque, and HYP levels. Furthermore, significant interactions were decomposed with follow-up repeated measures ANOVAs and independent or paired samples t-tests, Greenhouse-Geisser corrections were applied when sphericity was not met according to Maulchy's Test of Sphericity, and effect sizes were calculated for each comparison. Specifically, partial eta squared (η.sub.p.sup.2) for each ANOVA and Cohen's d for each Student's t-test were calculated. All data is presented mean ±Standard Error of the Mean. In addition, all statistical analyses were performed using IBM SPSS v. 25 (Armonk, N.Y.) and an alpha of p<0,05 was considered statistically significant for all comparisons,
Results
Test-Retest Reliability
[0108] Test-retest reliability was quantified using the 2,k model of Weir (supra, J Strength Cond Res 2005; 19(1):231-40) for mean differences (systematic error), ICCs, and SEM measured pre-supplementation versus post supplementation (8 weeks apart) from the placebo group (n=21). There was no significant mean difference for test versus retest for MVIC (
Adverse Events, Dietary Analyses, and Subject Adherence
[0109] There were no reported adverse events during the course of this study. In addition, there were no significant (p>0.05) differences for the dietary analyses of total caloric, carbohydrate, protein, or fat intake for pre-supplementation versus post-supplementation or between groups. Based on the number of capsules taken over the 8 week supplementation period, subject adherence was 95% (53 out of 56 capsules), 95% (53 out of 56 capsules), and 96% (54 out of 56 capsules) for the low dose, high dose, and placebo groups, respectively.
Absolute MVC Values and Percent Decline in MVIC
[0110] Total Group (n=63; 21 Per Group)
[0111] The 3 (Group: Low, High, and Placebo)×2 (Visit: Testing Visit 1 and Testing Visit 2)×2 (Fatigue: Pretest and Posttest) mixed factorial ANOVA indicated that there was no significant (p=0.267, η.sub.p.sup.2=0.043) 3-way or 2-way interactions (p=0.215, η.sub.p.sup.2=0.026; p=0.063, η.sub.p.sup.2=0.088; p=0.955, η.sub.p.sup.2=0.002). Furthermore, there was no significant (p=0.935, η.sub.p.sup.2=0.002) main effect for Group. There was, however, a significant (p=0,005, η.sub.p.sup.2=0.122) main effect for Fatigue (collapsed across Group and Visit), and the pairwise comparison indicated that Pretest MVIC (341.8±8.3 Nm) was significantly greater than Posttest MVIC (323.8±8.3 Nm).
[0112] The 1-way ANCOVA indicated that there was no significant (p=0.172, η.sub.p.sup.2=0.031) difference for pre-supplementation percent decline in MVIC, but that there was a significant (p=0.047; η.sub.p.sup.2=0.099) difference between groups for the adjusted (covaried for pre-supplementation values) mean post-supplement percent decline in MVIC. The pairwise comparisons indicated that the adjusted mean post-supplementation percent decline in MVIC was significantly (p=0.021) less for the high dose (9.1±2.0%) than the low dose (15.7±2.0%).
Upper 50.sup.th Percentile (n=30; 10 Per Group)
[0113] The 3 (Group: Low, High, and Placebo)×2 (Visit; Testing Visit 1 and Testing Visit 2)×2 (Fatigue: Pretest and Posttest) mixed factorial ANOVA indicated that there was no significant (p=0.169, η.sub.p.sup.2=0.123) 3-way or 2-way interactions containing Group (p=0.057, η.sub.p.sup.2=0.191; p=0.070, η.sub.p.sup.2=0.179). There was, however, a significant (p<0.001, η.sub.p.sup.2=0.434) main effect for Fatigue (collapsed across Group and Visit), and the pairwise comparison indicated that Pretest MVIC (394.8±9.0 Nm) was significantly greater than Posttest MVIC (357.6±10.5 Nm). In addition, there was no significant (p=0.168, η.sub.p.sup.2=0.168) main effect for Group.
[0114] The 1-way ANCOVA indicated that there was a significant (p=0.029, η.sub.p.sup.2=0.170) difference between groups for pre-supplementation percent decline in MVIC and a significant (p=0.042; η.sub.p.sup.2=0.217) difference between groups for the adjusted (covaried for pre-supplementation values) mean post-supplementation percent decline in MVIC. The pairwise comparisons indicated that the post-supplementation adjusted mean percent decline in MVIC was significantly (p=0.022 and 0.044) less for the high dose group (8.9±2.3%) than the low dose (17.0±2.4%) and placebo (16.0±2.4%) groups.
[0115] See
Lower 50.sup.th Percentile (n=33; 11 Per Group)
[0116] The 3 (Group: Low, High, and Placebo)×2 (Visit: Testing Visit 1 and Testing Visit 2)×2 (Fatigue: Pretest and Posttest) mixed factorial ANOVA indicated that there was no significant (p=0.825, η.sub.hu 2=0.013) 3-way interaction or any significant 2-way interaction (p=0.992, η.sub.p.sup.2<0.001; p=0.494, η.sub.p.sup.2=0.046; p=0.154, η.sub.p.sup.2=0.117). In addition, there was no significant (p=0.267, η.sub.p.sup.2=0.084) main effect for Group.
[0117] The 1-way ANCOVA indicated that there was not a significant (p=0.853, η.sub.p.sup.2=0.001) difference between groups for pre-supplementation percent decline in MVIC and no significant (p=0.445; η.sub.p.sup.2=0.054) difference between groups for the adjusted (covaried for pre-supplementation values) mean post-supplementation percent decline in MVIC.
[0118] Tables 1A, 1B, and 1C show MVIC data for study participants in the Low Dose Group (250 mg Shilajit), High Dose Group (500 mg Shilajit), and Placebo Group (No Shilajit). MVIC measurements are in N-m. Study participants in the Upper 50.sup.th percentile for their group are marked as Upper, and study participants in the Lower 50.sup.th percentile for their group are marked as Lower. Individuals 1-21 numbered within the groups are numbered independently of study identifiers.
TABLE-US-00001 TABLE 1A PreSuppl. PreSuppl. PostSuppl. PostSuppl. Low Dose PreMVIC PostMVIC PreMVIC PostMVIC PreSuppl. PostSuppl. Group (N-m) (N-m) (N-m) (N-m) % Decline % Decline UPPER 1 458 317 412 342 30.8 17.0 UPPER 2 516 439 502 439 14.9 12.5 UPPER 3 438 365 492 442 16.7 10.2 UPPER 4 363 252 201 193 30.6 4.0 UPPER 5 485 442 489 431 8.9 11.9 UPPER 6 487 430 381 370 11.7 2.9 UPPER 7 400 253 418 300 36.8 28.2 UPPER 8 364 276 349 275 24.2 21.2 UPPER 9 453 383 415 316 15.5 23.9 UPPER 10 463 402 384 318 13.2 17.2 UPPER 11 409 305 477 300 25.4 37.1 LOWER 12 329 304 285 284 7.6 0.4 LOWER 13 288 283 330 316 1.7 4.2 LOWER 14 340 305 489 268 10.3 45.2 LOWER 15 293 260 325 219 11.3 32.6 LOWER 16 289 225 312 244 22.1 21.8 LOWER 17 271 259 226 220 4.4 2.7 LOWER 18 345 263 239 220 23.8 7.9 LOWER 19 288 245 277 228 14.9 17.7 LOWER 20 287 237 264 240 17.4 9.1 LOWER 21 333 319 306 280 4.2 8.5
TABLE-US-00002 TABLE 1B PreSuppl. PreSuppl. PostSuppl. PostSuppl. High Dose PreMVIC PostMVIC PreMVIC PostMVIC PreSuppl. PostSuppl. Group (N-m) (N-m) (N-m) (N-m) % Decline % Decline UPPER 1 391 357 320 290 8.7 9.4 UPPER 2 356 306 392 305 14.0 22.2 UPPER 3 465 404 472 465 13.1 1.5 UPPER 4 410 375 373 358 8.5 4.0 UPPER 5 360 313 313 271 13.1 13.4 UPPER 6 418 287 320 313 31.3 2.2 UPPER 7 405 320 333 258 21.0 22.5 UPPER 8 505 435 411 409 13.9 0.5 UPPER 9 375 340 266 249 9.3 6.4 UPPER 10 381 353 389 343 7.3 11.8 UPPER 11 388 235 319 261 39.4 18.2 LOWER 12 331 309 314 306 6.6 2.5 LOWER 13 306 242 296 268 20.9 9.5 LOWER 14 299 213 293 264 28.8 9.9 LOWER 15 325 277 249 224 14.8 10.0 LOWER 16 351 329 326 313 6.3 4.0 LOWER 17 310 299 388 319 3.5 17.8 LOWER 18 315 290 345 336 7.9 2.6 LOWER 19 333 319 311 281 4.2 9.6 LOWER 20 337 297 276 245 11.9 11.2 LOWER 21 326 289 335 334 11.3 0.3
TABLE-US-00003 TABLE 1C PreSuppl. PreSuppl. PostSuppl. PostSuppl. Placebo PreMVIC PostMVIC PreMVIC PostMVIC PreSuppl. PostSuppl. Group (N-m) (N-m) (N-m) (N-m) % Decline % Decline UPPER 1 367 357 293 238 2.7 18.8 UPPER 2 362 331 349 329 8.6 5.7 UPPER 3 438 405 366 349 7.5 4.6 UPPER 4 395 370 402 347 6.3 13.7 UPPER 5 494 367 368 306 25.7 16.8 UPPER 6 358 300 340 330 16.2 2.9 UPPER 7 424 368 440 388 13.2 11.8 UPPER 8 394 393 310 247 0.3 20.3 UPPER 9 479 326 390 301 31.9 22.8 UPPER 10 552 461 447 391 16.5 12.5 UPPER 11 412 366 339 270 11.2 20.4 LOWER 12 314 288 360 331 8.3 8.1 LOWER 13 329 299 377 305 9.1 19.1 LOWER 14 337 257 428 369 23.7 13.8 LOWER 15 266 217 241 216 18.4 10.4 LOWER 16 219 205 254 177 6.4 30.3 LOWER 17 255 249 320 292 2.4 8.8 LOWER 18 332 280 350 284 15.7 18.9 LOWER 19 289 283 253 229 2.1 9.5 LOWER 20 346 314 412 326 9.2 20.9 LOWER 21 330 203 243 221 38.5 9.1
Absolute Concentric Peak Torque and Percent Decline in Concentric Peak Torque
[0119] Total Group (n=63; 21 Per Group)
[0120] The 3 (Group: Low, High, and Placebo)×2 (Visit; Testing Visit 1 and Testing Visit 2)×2 (Fatigue: Pretest and Posttest) mixed factorial ANOVA indicated that there was no significant (p=0.185, η.sub.p.sup.2=0.055) 3-way or 2-way interactions containing Group (p=0.582, η.sub.p.sup.2=0.018; p=0.524, η.sub.p.sup.2=0.021). In addition, there was no significant (p=0.572, η.sub.p.sup.2=0.018) main effect for Group.
[0121] The 1-way ANCOVA indicated that there was a significant (p<0.001, η.sub.p.sup.2=0.282) difference between groups for pre-supplementation percent decline in concentric peak torque, but there was no significant (p=0.274; η.sub.p.sup.2=0.043) difference between groups for the adjusted (covaried for pre-supplementation values) mean post-supplementation percent decline in concentric peak torque.
Upper 50.sup.th Percentile (n=30; 10 Per Group)
[0122] The 3 (Group: Low, High, and Placebo)×2 (Visit: Testing Visit 1 and Testing Visit 2)×2 (Fatigue: Pretest and Posttest) mixed factorial ANOVA indicated that there was a significant (p=0.004, η.sub.p.sup.2=0.339) 3-way Interaction. Subsequently, three (1 for each group) follow-up 2 (Visit: Testing Visit 1 and Testing Visit 2)×2 (Fatigue: Pretest and Posttest) repeated measures ANOVAs were used. For the low dose group, the follow-up analyses indicated that there was a significant (p=0.049, η.sub.p.sup.2=0.365) 2-way interaction, therefore, a paired t-test was used to examine pre-fatigue mean concentric peak torque at both pre- and post-supplementation. The t-test indicated that there was no significant (267.4±7.6 vs. 274.2±9.0 Nm; p=0.051, d=0.26) difference between pre-fatigue, pre-supplementation, peak, concentric torque and pre-fatigue, post-supplementation, peak, concentric torque. For the high dose group, the follow-analyses indicated that there was no significant (p<0.05) 2-way interaction or main effect related to fatigue. For the placebo group, the follow-up analyses indicated that there was a significant (p=0.022, η.sub.p.sup.2=0.458) 2-way interaction, therefore, a paired t-test was used to examine pre-fatigue, concentric, peak torque at both pre- and post-supplementation. The t-test indicated that pre-fatigue, pre-supplementation, concentric, peak torque was significantly (283.3±11.5 vs. 254.5±13.7 Nm; p=0.008, d=0.72) greater than pre-fatigue, post-supplementation, peak, concentric torque.
[0123] The 1-way ANCOVA indicated that there was a significant (p<0.001, η.sub.p.sup.2=0.622) difference between groups for pre-supplementation percent decline in concentric peak torque, but there was no significant (p=0.286; η.sub.p.sup.2=0.092) difference between groups for the adjusted (covaried for pre-supplementation values) mean post-supplementation percent decline in concentric peak torque.
Lower 50.sup.th Percentile (n=33; 11 Per Group)
[0124] The 3 (Group: Low, High, and Placebo)×2 (Visit: Testing Visit 1 and Testing Visit 2)×2 (Fatigue: Pretest and Posttest) mixed factorial ANOVA indicated that there was no significant (p=0.349, η.sub.p.sup.2=0.068) 3-way or 2-way interaction containing Group. In addition, there was no main effect (p=0.126; η.sub.p.sup.2=0.129) for Group.
[0125] The 1-way ANCOVA indicated that there was a significant (p=0.005, η.sub.p.sup.2=0.240) difference between groups for pre-supplementation percent decline in concentric peak torque, but there was no significant (p=0.841; η.sub.p.sup.2=0.0012) difference between groups for the adjusted (covaried for pre-supplementation values) mean post-supplementation percent decline in concentric peak torque.
TABLE-US-00004 TABLE 2A PreSup PreSup PreSup PreSup PstSup PstSup PstSup PstSup ! Peak Last PreSup Peak Last PreSup PreSup Peak Last PstSup Peak Last PstSup PstSup Torque Torque Set1 Torque Torque Set2 Total Torque Torque Set1 Torque Torque Set2 Total Low Dose Set1 Set1 % Set2 Set2 % % Set1 Set1 % Set2 Set2 % % (250 mg/ml) (N-m) (N-m) Decline (N-m) (N-m) Decline Decline (N-m) (N-m) Decline (N-m) (N-m) Deciine DecLine UPPER1 233.7 145.3 37.8 167.0 55.3 66.9 76.3 311.7 130.3 58.2 243.3 111.0 54.4 64.4 UPPER2 270.7 177.7 34.4 230.3 171.0 25.8 36.8 261.0 161.3 38.2 263.0 97.0 63.1 62.8 UPPER3 230.0 182.7 20.6 244.0 157.7 35.4 31.4 345.0 158.0 54.2 274.7 127.0 53.8 63.2 UPPER4 188.0 139.3 25.9 173.0 113.3 34.5 39.7 154.0 115.3 25.1 154.0 108.0 29.9 29.9 UPPER5 263.7 197.3 25.2 297.0 163.0 45.1 38.2 277.7 188.0 32.3 276.7 206.0 25.5 25.8 UPPER6 305.7 239.0 21.8 350.7 250.3 28.6 18.1 318.0 237.7 25.3 348.3 233.3 33.0 26.6 UPPER7 207.3 161.3 22.2 154.0 95.7 37.9 53.9 224.7 135.7 39.6 166.7 150.7 9.6 32.9 UPPER8 252.7 180.3 28.6 228.3 127.3 44.2 49.6 249.0 157.7 36.7 218.7 131.3 39.9 47.3 UPPER9 247.3 161.7 34.6 270.0 122.3 54.7 50.5 261.3 128.3 50.9 223.0 158.3 29.0 39.4 UPPER10 255.3 172.7 32.4 189.3 127.0 32.9 50.3 260.7 171.7 34.1 255.0 113.7 55.4 56.4 UPPER11 314.3 175.7 44.1 297.0 113.0 62.0 64.1 333.3 137.0 58.9 267.7 98.7 63.1 70.4 LOWER12 173.7 153.3 11.7 196.3 96.7 50.8 44.3 177.3 139.3 21.4 175.0 101.0 42.3 43.0 LOWER13 174.0 133.0 23.6 207.3 113.7 45.2 34.7 246.0 101.7 58.7 196.0 85.3 56.5 65.3 LOWER14 190.3 142.7 25.0 183.7 57.7 68.6 69.7 267.3 116.0 56.6 155.3 76.0 51.1 71.6 LOWER15 152.0 123.3 18.9 159.7 63.0 60.5 58.6 196.0 103.0 47.4 185.0 613 66.8 68.7 LOWER16 265.7 91.7 65.5 250.7 209.7 16.4 21.1 261.0 150.0 42.5 334.7 154.0 54.0 41.0 LOWER17 175.7 163.3 7.0 190.0 132.3 30.4 24.7 216.0 146.7 32.1 239.7 147.3 38.5 31.8 LOWER18 153.3 75.0 51.1 148.3 94.3 36.4 38.5 220.0 95.0 56.8 146.7 91.0 38.0 58.6 LOWER19 243.3 186.3 23.4 201.7 129.3 35.9 46.8 253.7 130.3 48.6 260.3 94.7 63.6 62.7 LOWER20 163.7 111.7 31.8 184.3 86.3 53.2 47.3 213.0 104.7 50.9 188.3 89.0 52.7 58.2 LOWER21 255.0 162.3 36.3 217.0 148.3 31.6 41.8 266.3 135.7 49.1 237.0 105.0 55.7 60.6
TABLE-US-00005 TABLE 2B PreSup PreSup PreSup PreSup PstSup PstSup PstSup PstSup Peak Last PreSup Peak Last PreSup PreSup Peak Last PstSup Peak Last PstSup PstSup Torque Torque Set1 Torque Torque Set2 Total Torque Torque Set1 Torque Torque Set2 Total High Dose Set1 Set1 % Set2 Set2 % % Set1 Set1 % Set 2 Set 2 % % (500 mg/ml) (N-m) (N-m) Decline (N-m) (N-m) Decline Decline (N-m) (N-m) Decline (N-m) (N-m) Decline Decline UPPER1 158.7 128.7 18.9 163.7 151.3 7.5 4.6 264.7 141.3 46.6 172.0 150.7 12.4 43.1 UPPER2 179.3 104.0 42.0 140.0 68.3 51.2 61.9 164.0 65.7 60.0 132.7 55.7 58.0 66.1 UPPER3 284.7 209.7 26.3 287.7 150.3 47.7 47.2 297.7 174.3 41.4 267.7 134.7 49.7 54.8 UPPER4 240.0 186.3 22.4 211.0 141.0 33.2 41.3 223.0 135.0 39.5 233.3 129.3 44.6 42.0 UPPER5 189.3 166.0 12.3 155.7 126.3 18.8 33.3 168.0 98.7 41.3 148.0 61.7 58.3 63.3 UPPER6 198.3 147.7 25.5 218.0 135.0 38.1 31.9 229.7 165.0 28.2 208.7 108.3 48.1 52.8 UPPER7 245.7 84.3 65.7 171.0 69.7 59.3 71.6 219.3 93.7 57.3 182.0 65.0 64.3 70.4 UPPER8 246.3 183.0 25.7 274.7 147.0 46.5 40.3 304.0 160.0 47.4 234.7 143.7 38.8 52.7 UPPER9 201.0 140.7 30.0 209.7 152.0 27.5 24.4 191.3 163.0 14.8 280.3 187.7 33.1 1.9 UPPER10 306.7 170.0 44.6 267.0 139.0 47.9 54.7 275.7 110.3 60.0 260.3 98.0 62.4 64.4 UPPER11 239.3 123.0 48.6 203.0 88.3 56.5 63.1 230.0 127.3 44.6 233.3 108.7 53.4 52.8 LOWER12 280.7 180.3 35.7 240.7 157.0 34.8 44.1 261.3 180.7 30.9 273.0 139.3 49.0 46.7 LOWER13 154.0 100.0 35.1 205.3 128.7 37.3 16.5 159.0 106.7 32.9 146.0 83.0 43.2 47.8 LOWER14 255.7 158.7 37.9 241.3 124.3 48.5 51.4 287.0 128.0 55.4 235.0 130.7 44.4 54.5 LOWER15 184.0 129.0 29.9 195.7 157.3 19.6 14.5 234.3 165.7 29.3 224.3 197.7 11.9 15.6 LOWER16 234.0 157.7 32.6 233.7 129.7 44.5 44.6 258.3 158.0 38.8 232.0 154.3 33.5 40.3 LOWER17 227.7 126.7 44.4 228.0 98.3 56.9 56.8 283.3 144.0 49.2 258.7 137.0 47.0 51.6 LOWER18 277.7 219.0 21.1 299.7 172.3 42.5 37.9 285.3 230.7 19.2 296.0 186.7 37.0 34.6 LOWER19 263.0 162.3 38.3 217.0 148.3 31.6 43.6 241.0 188.7 21.7 230.3 135.3 41.2 43.8 LOWER20 251.0 158.7 35.8 234.3 132.7 43.4 47.1 217.3 163.0 25.0 191.0 161.7 15.4 25.6 LOWER21 251.7 162.0 35.6 288.7 123.7 57.2 50.9 251.0 150.7 40.0 247.7 118.7 52.1 52.7
TABLE-US-00006 TABLE2C PreSup PreSup PreSup PreSup PstSup PstSup PstSup PstSup Peak Last PreSup Peak Last PreSup PreSup Peak Last PstSup Peak Last Torque Torque Set1 Torque Torque Set2 Total Torque Torque Set1 Torque Torque PstSup PstSup Set1 Set1 % Set2 Set2 % % Set1 Set1 % Set2 Set2 Set2 Total Placebo (N-m) (N-m) Decline (N-m) (N-m) Decline Decline (N-m) (N-m) Decline (N-m) (N-m) % % UPPER1 228.7 176.7 22.740 257 105.7 58.884 53.790 252.3 123.66 50.990 244.7 72.666 70.299 71.202 UPPER2 224.0 193.7 13.541 212.66 201.7 5.1724 9.9702 195.3 175 10.409 189.0 156 17.460 20.136 UPPER3 327.7 139.3 57.477 311.65 117.3 62.352 64.191 296.0 184.66 37.612 268.0 134.33 49.875 54.617 UPPER4 220.3 174.3 20.877 269 149.0 44.609 32.375 264.3 193.33 26.860 279.0 172 38.351 34.930 UPPER5 285.7 123.7 56.709 211 100.0 52.606 64.994 237.7 179.66 24.403 238.0 122.66 48.459 48.387 UPPER6 215.0 144.7 32.713 241 128.7 46.611 40.155 252.3 157 37.780 258.7 144.66 44.072 42.658 UPPER7 242.7 221.7 8.6538 276.66 196.0 29.156 19.230 264.7 182.33 31.108 295.7 193 34.723 27.078 UPPER8 225.3 139.3 38.165 283.33 170.3 39.882 24.408 256.0 194 24.218 253.0 182.66 27.799 28.645 UPPER9 331.3 208.0 37.223 330 169.0 48.787 48.993 313.0 152.33 51.331 277.7 150.66 45.738 51.863 UPPER10 292.7 174.3 40.432 254 159.3 37.270 45.558 261.7 224 14.394 271.3 175.0 35.503 33.121 UPPER11 325.7 157.0 51.791 283.66 134.3 52.643 58.751 298.3 144.33 51.620 265.0 112.33 57.610 62.346 LOWER12 181.0 162.7 10.128 199.33 147.7 25.919 18.416 248.3 194 21.879 255.7 165.33 35.332 33.422 LOWER13 161.3 125.3 22.314 188.66 98.0 48.056 39.256 268.0 126.66 52.736 202.0 122.33 39.438 54.353 LOWER14 286.7 96.0 66.511 171.66 92.0 46.407 67.906 257.7 133 48.382 204.7 94.333 53.908 63.389 LOWER15 255.0 109.7 56.993 228 101.0 55.701 60.392 172.3 152.66 11.411 198.0 129.33 34.680 24.951 LOWER16 160.7 152.7 4.9792 244 129.3 46.994 19.502 234.0 119 49.145 218.0 97 55.504 58.547 LOWER17 160.0 152.3 4.7916 163 120.7 25.971 24.583 141.3 111.66 20.990 145.3 132 9.1743 6.6037 LOWER18 217.3 148.0 31.901 249.66 161.3 35.380 25.766 302.7 203.33 32.819 238.3 160.66 32.587 46.916 LOWER19 148.7 134.0 9.8654 219.66 140.0 36.267 5.8295 209.3 112.66 46.178 218.3 126.33 42.137 39.649 LOWER20 243.7 139.7 42.681 168.33 158.3 5.9405 35.020 208.3 149.66 28.16 229.7 135.66 40.928 34.88 LOWER21 242.0 188.0 22.314 290.33 142.3 50.975 41.184 235.3 152 35.410 280.3 172.66 38.406 26.628
Absolute Baseline HYP and Percent Change In HYP
[0126] Total Group (n=63; 21 Per Group)
[0127] The 3 (Group: Low, High, and Placebo)×2 (Time: Baseline and 48 hr Post)×2 (Supplementation: Pre- and Post Supplementation) mixed factorial ANOVA indicated that there was no significant (p=0.345, η.sub.p.sup.2=0.035) 3-way or 2-way interaction as well as no main effects.
[0128] The 1-way ANCOVA indicated that there was no significant (p=0.122, η.sub.p.sup.2=0.040) difference between groups for pre-supplementation percent decline (Baseline to 48-hrs post exercise) in HYP as well as no significant (p=0.945; η.sub.p.sup.2=0.002) difference between groups for the adjusted (covaried for pre-supplementation values) mean post-supplement percent decline in HYP. An additional 1-way ANCOVA was used to evaluate the percent change in Baseline HYP pre-supplementation to Baseline HYP past-supplementation, which indicated that there was a significant (p=0.122, η.sub.p.sup.2=0.105) difference between groups for pre-supplementation Baseline HYP levels, but there was no difference (p=0.252, η.sub.p.sup.2=0.046) between groups for the adjusted (covaried for pre-supplementation values) mean past-supplementation Baseline HYP levels.
Upper 50.sup.th Percentile (n=30; 10 Per Group)
[0129] The 3 (Group: Low, High, and Placebo)×2 (Time: Baseline and 48 hr Post)×2 (Supplementation: Pre- and Post-Supplementation) mixed factorial ANOVA indicated that there was no significant (p=0.256, η.sub.p.sup.2=0.096) 3-way or 2-way interaction as well as no main effects.
[0130] The 1-way ANCOVA indicated that there was no significant (p=0.594, η.sub.p.sup.2=0.079) difference between groups for pre-supplementation percent decline (Baseline to 48-hrs post exercise) in HYP as well as no significant (p=0.453; η.sub.p.sup.2=0.022) difference between groups for the adjusted (covaried for pre-supplementation values) mean post-supplementation percent decline in HYP. An additional 1-way ANCOVA was used to evaluate the percent change in Baseline HYP pre-supplementation to Baseline HYP post-supplementation, which indicated that there was no significant (p=0.410, η.sub.hu 2=0.026) difference between groups for pre-supplementation Baseline HYP levels, however, there was a significant difference (p=0.041, η.sub.p.sup.2=0.218) between groups for the adjusted (covaried far pre-supplementation values) mean post-supplementation Baseline HYP levels. Pairwise comparisons indicated that the adjusted mean post-supplementation Baseline HYP for the high dose group (1.5±0.3 μg.Math.mL.sup.−1) was significantly (p=0.034 and p=0.024) lower than both the low dose group (2.4±0.3 μg.Math.mL.sup.−1) and placebo group (2.4±0.3 μg.Math.mL.sup.−1).
[0131] See
Lower 50.sup.th Percentile (n=33; 11 Per Group)
[0132] The 3 (Group: Low, High, and Placebo)×2 (Time: Baseline and 48 hr Post)×2 (Supplementation: Pre- and Post-Supplementation) mixed factorial ANOVA indicated that there was no significant (p=0.918, η.sub.p.sup.2=0.006) 3-way or 2-way interaction as well as no main effect for Group. There was, however, a significant (p=0.049, η.sub.p.sup.2 =0.124) main effect for Supplementation (collapsed across Group and Time). Furthermore, the pairwise comparison indicated that post-supplementation HYP levels (1.6±0.1 μg.Math.mL.sup.−1) were significantly (p=0.049, d=0.75 μg.Math.mL.sup.−1) greater than pre-supplementation (1.8±0.1 μg.Math.mL.sup.−1).
[0133] The 1-way ANCOVA indicated that there was no significant (p=0.058, η.sub.p.sup.2=0.118) difference between groups for pre-supplementation percent decline (Baseline to 48-hrs post exercise) in HYP as well as no significant (p=0.760; η.sub.p.sup.2=0.019) difference between groups for the adjusted (covaried for pre-supplementation values) mean post-supplementation percent decline in HYP. An additional 1-way ANCOVA was used to evaluate the percent change in Baseline HYP pre-supplementation to Baseline HYP post-supplementation, which indicated that there was no (p=0.597, η.sub.p.sup.2=0.010) difference between groups for pre-supplementation Baseline HYP levels as well as no difference (p=0.540, η.sub.p.sup.2=0.042) between groups for the adjusted (covaried for pre-supplementation values) mean post-supplementation Baseline HYP levels.
[0134] The 8 weeks of PrimaVie® Shilajit supplementation described above had no effects on the pre-fatigue MVIC, pre-fatigue concentric peak torque, or body weight values of the subjects. Individuals A-U designated within the groups are designated independently of study identifiers.
TABLE-US-00007 TABLE 3A Base- PostSuppl. line 48-Hr Baseline PostSuppl. Low Dose HYP (ug/ % HYP 48-Hr % Group (ug/ml) ml) Change (ug/ml) (ug/ml) Change UPPER A 3.314 1.920 −42 2.191 1.121 −49 UPPFR B 2.482 2.717 9 2.573 2.744 7 UPPER C 3.301 2.378 −30 1.890 2.562 36 UPPER D 2.399 1.654 −31 3.278 2.140 −35 UPPER E 3.409 2.324 −32 1.910 1.473 −23 UPPER F 4.747 2.081 −56 1.693 1.736 3 UPPER G 2.609 3.248 25 2.425 2.049 −16 UPPER H 4.300 3.923 −9 4.229 2.955 −30 UPPER I 2.497 2.292 −8 0.979 2.723 178 UPPER J 2.001 3.139 57 2.620 2.201 −16 LOWER K 1.084 0.917 −15 1.501 2.151 43 LOWER L 1.388 1.010 −27 1.389 0.780 −44 LOWER M 1.432 1.188 −17 0.581 1.854 219 LOWER N 1.928 1.200 −38 0.948 1.395 47 LOWER O 1.669 1.188 −29 2.247 1.266 −44 LOWER P 1.788 1.886 5 2.084 1.880 −10 LOWER Q 1.588 1.355 −15 1.314 1.927 47 LOWER R 1.654 1.690 2 1.577 2.857 81 LOWER S 1.545 1.455 −6 1.705 2.697 58 LOWER T 1.488 1.647 11 1.529 1.183 −23 LOWER U 0.689 0.975 41 1.089 1.049 −4
TABLE-US-00008 TABLE 3B Base- PostSuppl. line 48-Hr Baseline PostSuppl. High Dose HYP (ug/ % HYP 48-Hr % Group (ug/ml) ml) Change (ug/ml) (ug/ml) Change UPPER A 4.16 1.64 −61 1.99 1.35 −32 UPPER B 3.84 2.18 −43 0.88 2.08 136 UPPER C 3.66 2.21 −40 2.67 1.56 −42 UPPER D 3.44 1.79 −48 1.01 3.30 227 UPPER E 2.96 1.67 −44 1.79 1.42 −21 UPPER F 2.50 2.91 16 1.11 1.54 39 UPPER G 2.21 1.37 −38 1.54 2.28 49 UPPER H 2.17 2.74 26 1.14 1.51 33 UPPER I 1.93 1.25 −35 0.79 0.83 5 UPPER J 1.86 2.43 30 2.05 2.12 4 LOWER K 1.85 1.06 −43 1.87 1.76 −6 LOWER L 1.82 1.76 −4 1.71 1.76 3 LOWER M 1.81 1.87 4 2.60 1.76 −32 LOWER N 1.79 1.27 −29 3.63 4.28 18 LOWER O 1.77 0.94 −47 1.06 1.27 20 LOWER P 1.74 1.29 −26 1.14 1.42 25 LOWER Q 1.71 2.21 29 1.51 1.59 5 LOWER R 1.69 1.67 −1 1.51 1.04 −31 LOWER S 1.59 0.93 −42 1.30 2.06 58 LOWER T 1.52 1.81 20 1.37 1.13 −18 LOWER U 1.38 2.04 48 2.20 3.62 64
TABLE-US-00009 TABLE 3C Base- PostSuppl. PostSuppl. line 48-Hr Baseline 48-Hr Placebo HYP (ug/ % HYP HYP % Group (ug/ml) ml) Change (ug/ml) (ug/ml) Change UPPER A 4.80 3.46 −28 3.02 1.55 −49 UPPER B 3.38 2.07 −39 2.23 4.90 120 UPPER C 3.18 3.28 3 3.39 2.97 −13 UPPER D 3.02 1.83 −39 1.10 0.85 −23 UPPER E 2.49 2.37 −5 1.13 2.01 77 UPPER F 2.37 2.18 −8 2.07 1.38 −33 UPPER G 2.35 1.74 −26 3.73 1.96 −48 UPPER H 2.31 1.96 −15 2.00 1.96 −2 UPPER I 2.21 3.80 72 3.40 1.57 −54 UPPER J 1.93 2.73 41 1.78 2.07 16 LOWER K 1.87 1.77 −6 2.17 2.70 24 LOWER L 1.86 2.12 14 1.47 2.31 57 LOWER M 1.84 2.03 10 1.64 1.79 9 LOWER N 1.58 2.86 80 0.97 1.91 96 LOWER O 1.52 3.26 114 1.42 6.81 379 LOWER P 1.48 3.44 132 1.58 1.98 26 LOWER Q 1.39 1.63 18 1.23 1.33 8 LOWER R 1.34 1.32 −1 3.01 3.12 4 LOWER S 1.26 1.47 16 1.63 2.05 25 LOWER T 1.17 0.98 −16 0.94 0.94 −0.3 LOWER U 1.08 1.56 43 2.32 2.40 4
[0135] Table 4 provides the
[0136] The 1-way ANCOVA and pairwise comparisons indicated that the adjusted mean post-supplementation percent decline in MVJC was significantly (p=0,021; d=0.42) less for the high dose (9.1±2.0%) than the low dose (15.7±2.0%).
TABLE-US-00010 TABLE 4 Descriptive Characteristics (
Discussion
[0137] The above Example shows that the administration of 500 mg.Math.d.sup.−1 of PrimaVie® Shilajit to subjects for 8 weeks reduced muscle fatigue, increasing retention of maximal muscular strength following a fatiguing task and decreasing baseline HYP in the upper 50.sup.th percentile of subjects.
[0138] Specifically, for the total group (n=63; 21 per group), the percent decline in MVIC following the fatiguing protocol was less for the 500 mg.Math.d.sup.−1 of PrimaVie® Shilajit group than the 250 mg.Math.d.sup.−1 group. In addition, the examination of the sub-sample of subjects in the upper 50.sup.th percentile of MVIC indicated that the high dose group was more resistant to fatigue and retained a greater level of maximal muscular strength than both the low dose and placebo groups.
[0139] The above data shows the beneficial effects of PrimaVie° Shilajit supplementation on fatigue-related performance outcomes using a resistance exercise model. Previous studies, however, have examined the effects of PrimaVie° Shilajit supplementation on mitochondrial indices of exercise performance that may have implications for the findings of the present study. For instance, Bhattacharyya et al. (Pharmacologyonline 2009; 1:817-25) used a forced swimming task in mice to examine the effects of PrimaVie® Shilajit supplementation on indices of mitochondrial function including post-exercise muscle ATP concentration and adenylate energy charge. Oral PrimaVie® Shilajit supplementation (30 mg.Math.kg.sup.−1 of body weight for 4 days) resulted in a significantly greater (p<0.001) post-exercise ATP concentration of 0.49±0.05 μmol.Math.g.sup.−1 of muscle compared to 0.25±0.05 μmol.Math.g.sup.−1 for the swimming only group without PrimaVie® Shilajit supplementation. Furthermore, the adenylate energy charge, which is an index of the energy status of the cell and depends on the relative concentrations of ATP, adenosine diphosphate, and adenosine monophosphate, was significantly (p<0.05) greater post-exercise for the PrimaVie® Shilajit supplementation plus swimming group (0.62±0.06 units) compared to the swimming only without PrimaVie® Shilajit supplementation (0.52±0.04 units). Bhattacharyya et al. (2009) hypothesized that the augmented mitochondrial function, improved energy status, and upregulated ATP synthesis were the result of PrimaVie® Shilajit supplementation due to “. . . its potent electron transfer capacity and antioxidant activity” (p. 823).
[0140] Without being bound by theory, the enhanced mitochondrial function reported by Bhattacharyya et al. (2009) may at least in part explain the improved resistance to fatigue found in the present study for the 500 mg.Math.d.sup.−1 PrimaVie® Shilajit group. Krustrup et al. (“ATP and heat production in human skeletal muscle during dynamic exercise: higher efficiency of anaerobic than aerobic ATP resynthesis” J Physiol 2003; 549(1):255-69) demonstrated that mitochondrial respiration contributes to the resynthesis of ATP during high intensity leg extension muscle actions similar to those used during the fatiguing protocols in the present study. Furthermore, given the beneficial findings for the upper 50.sup.th percentile of MVIC group in the present study, this explanation may be particularly applicable to an athlete and/or other subject involved in resistance training. Improved mitochondrial functioning may also explain the findings of a recent unpublished, pilot study of six adult humans that found improved performance on the Harvard Step Test following 15 days of supplementation with 200 mg of PrimaVie® Shilajit.
[0141] In one embodiment of this invention, Shilajit (such as PrimaVie® Shilajit) in conjunction with resistance training enhances strength gains as well as increases in muscle mass and body Weight due to Shilajit's effect on circulating testosterone levels. PrimaVie® Shilajit plus resistance training increases muscular strength, size, and endurance. See for instance Pandit et al, (Andrologia 2016; 48(5):570-5), reporting that 500 mg.Math.d.sup.−1 PrimaVie® Shilajit for 90 days increased baseline testosterone (4.84±1.54 ng.Math.mL.sup.−1), free testosterone (15.36±7.17 pg.Math.mL.sup.−1), and dehydroepiandrosterone (145.09±53.17 μg.Math.dL.sup.−1) by 20.45%, 19.14%, and 31.35%, respectively in healthy adult men. in an embodiment, a method of the present invention includes the administration of PrimaVie® Shilajit along with resistance training to synergistically increase muscular strength, size, and appearance.
[0142] In the above Example, 8 weeks of PrimaVie® Shilajit supplementation at 500 mg.Math.d.sup.−1 resulted in a 29% post-supplementation reduction in baseline hydroxyproline (HYP) in the sub-sample of subjects in the upper 50.sup.th percentile for pre-supplementation HYP. The reduced baseline HYP shows a reduction in collagen degradation following supplementation. Previous studies (Suominen et al., “Effects of physical training on metabolism of connective tissues in young mice” Acta Physiol Scand 1980; 108(1):17-22; Tofas et al., “Plyometric exercise increases serum indices of muscle damage and collagen breakdown” J Strength Cond Res 2008; 22(4490-6; Brown et al., “Indices of skeletal muscle damage and connective tissue breakdown following eccentric muscle contractions” Eur J Appl Physiol Occup Physiol 1997; 75(4369-74; Kovanen et al., “Collagen of slow twitch and fast twitch muscle fibres in different types of rat skeletal muscle” Eur J Appl Physiol Occup Physiol 1984; 52(4235-42) have used HYP as an indirect indicator of collagen degradation from muscle and connective tissues. Exercise-induced muscle damage and soreness (Clarkson et al., “Exercise-induced muscle damage in humans” Am J Phys Med Rehabil 2002; 81(11):S52-69), connective tissue disruption (Saxton et al., “Neuromuscular dysfunction following eccentric exercise” Med Sci Sports Exerc” 1995; 27(8):1185-93), and elevated HYP (Brown et al., “Indices of skeletal muscle damage and connective tissue breakdown following eccentric muscle contractions” Eur J Appl Physiol Occup Physiol 1997; 75(4):369-74; Brown et al., “Indirect evidence of human skeletal muscle damage and collagen breakdown after eccentric muscle actions” J Sports Sci 1999; 17(5):397-402) often result from eccentric, but not concentric, muscle actions. The lack of acute (baseline versus 48 hr post-exercise) changes in HYP in the present study following the pre-supplementation and post-supplementation fatiguing work bouts were likely due to the use of concentric muscle actions, which typically cause little or no muscle damage (Clarkson et al., “Exercise-induced muscle damage in humans” Am J Phys Med Rehabil 2002; 81(11):S52-69; Byrne et al., “Neuromuscular function after exercise-induced muscle damage” Sport Med 2004 Jan. 1; 34(1):49-69). In one embodiment, the post-supplementation reduction in baseline HYP was due to a reduction in collagen degradation associated with connective tissues, but not muscle, showing that 8 weeks of PrimaVie® Shilajit supplementation at 500 mg.Math.d.sup.−1 supported connective tissue health associated with tendons and ligaments. See also Baar et al., “Minimizing injury and maximizing return to play: Lessons from engineered ligaments” Sport Med 2017; 47(45-11.
[0143] In one embodiment, a subject of the present invention is a competitive and/or recreational athlete involved in high volumes of chronic exercise who exhibits elevated exercise-induced collagen degradation. Das et al. (J Med Food 2016; 19(7):701-9) found that 8 weeks of PrimaVie® Shilajit supplementation at 500 mg.Math.d.sup.−1 increased mRNA expression of collagen, the major structural protein in the skeletal muscle extracellular matrix, which accounts for 6% of the weight of tendinous muscle. See also for instance Gisselman et al., “Musculoskeletal overuse injuries and heart rate variability: Is there a link?” Med Hypotheses 2016; 87:1-7; Magnusson et al., “The impact of loading, unloading, ageing and injury on the human tendon” J Physiol 2018; 597(5):1283-1298; Perry, “Exercise, injury and chronic inflammatory lesions” British Medical Bulletin 1992; 1; 48(3):668-82).
[0144] In an embodiment, a subject of a method of the present invention has impaired collagen function, such as subject having Padget's disease, Ehlers-Danos Syndrome, Osteogenesis Imperfecta, and/or another collagen-related disorder.
[0145] In an embodiment, a subject of a method of the present invention is an athlete whose exercise conditions cause muscle damage such as high intensity eccentric muscle actions in healthy individuals.
[0146] The use of the terms “a,” “an,” “the,” and similar referents in the context of describing the present invention (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. Use of the term “about” is intended to describe values either above or below the stated value in a range of approximately ±10%; in other embodiments, the values may range in value above or below the stated value in a range of approximately ±5%; in other embodiments, the values may range in value above or below the stated value in a range of approximately ±2%; in other embodiments, the values may range in value above or below the stated value in a range of approximately ±1%. The preceding ranges are intended to be made clear by context, and no further limitation is implied. All method steps described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise stated. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0147] While in the foregoing specification the present invention has been described in relation to certain embodiments thereof, and many details have been put forth for the purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein can be varied considerably without departing from the basic principles of the invention.
[0148] The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof, and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.